CTNM · Insider Trading
Contineum Therapeutics, Inc. Class A Common Stock
Every open-market purchase and sale reported by CTNM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Carmine N. Stengone | CEO and President | MIXED | — | −$38.62K |
| 2026-08-03 | Carmine N. Stengone | CEO and President | MIXED | — | −$37.50K |
| 2026-07-10 | Daniel S. Lorrain | Chief Scientific Officer | MIXED | — | −$15.59K |
| 2026-07-08 | Carmine N. Stengone | CEO and President | MIXED | — | −$37.48K |
| 2026-07-02 | Daniel S. Lorrain | Chief Scientific Officer | MIXED | −4,170 | −$561.24K |
| 2026-07-01 | Tim Watkins | CMO & Head of Development | MIXED | — | −$124.84K |
| 2026-07-01 | Carmine N. Stengone | CEO and President | MIXED | — | −$149.35K |
| 2026-06-26 | Sarah Boyce | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Evert B. Schimmelpennink | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Gines Diego Miralles | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Todd R. Brady | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Lori Lyons-Williams | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Olivia C Ware | Director | A | +19,000 deriv. | — |
| 2026-06-26 | Troy A. Ignelzi | Director | A | +19,000 deriv. | — |
| 2026-06-01 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$54.86K |
| 2026-05-01 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$54.69K |
| 2026-04-06 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$56.01K |
| 2026-03-02 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$62.59K |
| 2026-03-02 | Tim Watkins | CMO & Head of Development | MIXED | — | −$37.97K |
| 2026-02-26 | Carmine N. Stengone | CEO and President | MIXED | — | −$104.78K |
| 2026-02-26 | Daniel S. Lorrain | Chief Scientific Officer | MIXED | — | −$121.96K |
| 2026-02-20 | Daniel S. Lorrain | Chief Scientific Officer | MIXED | — | −$1.50K |
| 2026-02-13 | Daniel S. Lorrain | Chief Scientific Officer | MIXED | — | −$6.00K |
| 2026-02-13 | Carmine N. Stengone | CEO and President | MIXED | — | −$5.90K |
| 2026-02-05 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$62.31K |
| 2026-01-30 | John Stephen Healy | General Counsel and Corp Sec | A | +206,411 deriv. | — |
| 2026-01-30 | Daniel S. Lorrain | Chief Scientific Officer | A | +166,500 deriv. | — |
| 2026-01-30 | Peter T Slover | Chief Financial Officer | A | +192,000 deriv. | — |
| 2026-01-30 | Tim Watkins | CMO & Head of Development | MIXED | — | −$34.94K |
| 2026-01-30 | Carmine N. Stengone | CEO and President | A | +445,000 deriv. | — |
| 2026-01-06 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$43.54K |
| 2025-12-30 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −4,170 | −$51.01K |
| 2025-12-30 | Tim Watkins | CMO & Head of Development | MIXED | — | −$27.31K |
| 2025-06-26 | Sarah Boyce | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Gines Diego Miralles | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Troy A. Ignelzi | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Todd R. Brady | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Evert B. Schimmelpennink | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Olivia C Ware | Director | A | +14,750 deriv. | — |
| 2025-06-26 | Lori Lyons-Williams | Director | A | +14,750 deriv. | — |
| 2025-04-28 | Tim Watkins | CMO & Head of Development | A | +286,000 deriv. | — |
| 2025-03-17 | Gines Diego Miralles | Director | A | +29,500 deriv. | — |
| 2025-01-31 | John Stephen Healy | General Counsel and Corp Sec | A | +63,589 deriv. | — |
| 2025-01-31 | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | A | +110,000 deriv. | — |
| 2025-01-31 | Peter T Slover | Chief Financial Officer | A | +110,000 deriv. | — |
| 2025-01-31 | Carmine N. Stengone | CEO and President | A | +300,000 deriv. | — |
| 2025-01-31 | Daniel S. Lorrain | Chief Scientific Officer | A | +113,700 deriv. | — |
| 2024-11-27 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −1,010 | −$16.18K |
| 2024-11-20 | Daniel S. Lorrain | Chief Scientific Officer | Sell | −6,190 | −$101.42K |
| 2024-08-14 | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | M | +12,800 | +$12.93K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel S. Lorrain | Chief Scientific Officer | 145,337 | $1.58M |
| Tim Watkins | CMO & Head of Development | 19,794 | $214.57K |
| Carmine N. Stengone | CEO and President | 19,717 | $213.73K |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 12,800 | $138.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTNM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.